CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial

Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development workInvestors participating in the financing include QUBIS, the commercialization arm of Queen’s University in Belfast, Invest Northern Ireland, CoFund NI, managed by Clarendon Fund Managers, Techstart Ventures as well as US and UK-based private investors. CV6 has also received a Grant for R&D from Invest Northern Ireland* to support the Phase 1a trial.

Read the full release